Scoping Review: The Role of Psychedelics in the Management of Chronic Pain

References

• Zia FZ, Baumann MH, Belouin SJ., et al. Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs. Neuropharmacology. 2023:233. doi:10.1016/J.NEUROPHARM.2023.109528
   Web of Science ®Google Scholar
• Smith TJ, Hillner BE. The cost of pain. JAMA Network Open. 2019;2(4):e191532–e191532. doi:10.1001/JAMANETWORKOPEN.2019.1532
   PubMed Web of Science ®Google Scholar
• Dahlhamer J, Lucas J, Zelaya C, et al. Prevalence of chronic pain and high-impact chronic pain among adults - United States, 2016. MMWR Morb Mortal Wkly Rep. 2018;67(36):1001–1006. doi:10.15585/MMWR.MM6736A2
   PubMed Web of Science ®Google Scholar
• JEC Analysis Finds Opioid Epidemic Cost U.S. Nearly $1.5 Trillion in 2020 | u.S. Representative Don Beyer. Available from: https://beyer.house.gov/news/documentsingle.aspx?DocumentID=5684. Accessed August 5, 2023.
   Google Scholar
• Ghose R, Forati AM, Mantsch JR. Impact of the COVID-19 pandemic on opioid overdose deaths: a spatiotemporal analysis. J Urban Health. 2022;99(2):316. doi:10.1007/S11524-022-00610-0
   PubMed Web of Science ®Google Scholar
• Elman I, Pustilnik A, Borsook D. Beating pain with psychedelics: matter over mind? Neurosci Biobehav Rev. 2022;134:104482. doi:10.1016/J.NEUBIOREV.2021.12.005
   PubMed Web of Science ®Google Scholar
• Schindler EAD. Psychedelics in the treatment of headache and chronic pain disorders. Curr Top Behav Neurosci. 2022;56:261–285. doi:10.1007/7854_2022_365
   PubMedGoogle Scholar
• Kurtz JS, Patel NA, Gendreau JL, et al. The use of psychedelics in the treatment of medical conditions: an analysis of currently registered psychedelics studies in the American drug trial registry. Cureus. 2022;14(9). doi:10.7759/CUREUS.29167
   Web of Science ®Google Scholar
• Drug Scheduling. Available from: https://www.dea.gov/drug-information/drug-scheduling. Accessed August 24, 2023.
   Google Scholar
• Lyes M, Yang KH, Castellanos J, Furnish T. Microdosing psilocybin for chronic pain: a case series. Pain. 2023;164(4):698–702. doi:10.1097/J.PAIN.0000000000002778
   PubMed Web of Science ®Google Scholar
• Glynos NG, Pierce J, Davis AK, McAfee J, Boehnke KF. Knowledge, perceptions, and use of psychedelics among individuals with fibromyalgia. J Psychoactive Drugs. 2023;55(1):73–84. doi:10.1080/02791072.2021.2022817
   PubMed Web of Science ®Google Scholar
• Schindler EAD, Sewell RA, Gottschalk CH, et al. Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: results from a randomized, double-blind, placebo-controlled trial. Headache. 2022;62(10):1383–1394. doi:10.1111/HEAD.14420
   PubMed Web of Science ®Google Scholar
• Das S, Maiti T. Lysergic acid diethylamide as an analgesic agent in patients with terminal illnesses. Pain Manag. 2020;10(1):9–12. doi:10.2217/PMT-2019-0043
   PubMed Web of Science ®Google Scholar
• Rjosk V, Kaminski E, Hoff M, et al. Mirror visual feedback-induced performance improvement and the influence of hand dominance. Front Hum Neurosci. 2016;9:174714. doi:10.3389/FNHUM.2015.00702/BIBTEX
   Web of Science ®Google Scholar
• Schindler EAD, Gottschalk CH, Weil MJ, Shapiro RE, Wright DA, Sewell RA. Indoleamine hallucinogens in cluster headache: results of the clusterbusters medication use survey. J Psychoactive Drugs. 2015;47(5):372–381. doi:10.1080/02791072.2015.1107664
   PubMed Web of Science ®Google Scholar
• Karst M, Halpern JH, Bernateck M, Passie T. The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: an open, non-randomized case series. Cephalalgia. 2010;30(9):1140–1144. doi:10.1177/0333102410363490
   PubMed Web of Science ®Google Scholar
• Ramachandran V, Chunharas C, Marcus Z, Furnish T, Lin A. Relief from intractable phantom pain by combining psilocybin and mirror visual-feedback (MVF). Neurocase. 2018;24(2):105–110. doi:10.1080/13554794.2018.1468469
   PubMed Web of Science ®Google Scholar
• Fanciullacci M, Bene E, Del Franchi G, Sicuteri F. Brief report: phantom limp pain: sub-hallucinogenic treatment with lysergic acid diethylamide (LSD-25). Headache. 1977;17(3):118–119. doi:10.1111/J.1526-4610.1977.HED1703118.X
   PubMed Web of Science ®Google Scholar
• Kuromaru S. The effect of LSD on the phantom limb phenomenon - PubMed. J Lancet. 1967;87(1):22–27.
   PubMedGoogle Scholar
• Sewell RA, Halpern JH, Pope HG. Response of cluster headache to psilocybin and LSD. Neurology. 2006;66(12):1920–1922. doi:10.1212/01.WNL.0000219761.05466.43
   PubMed Web of Science ®Google Scholar
• Drug Scheduling. Avaialable from: https://www.dea.gov/drug-information/drug-scheduling. Accessed February 2, 2024.
   Google Scholar
• Preller KH, Herdener M, Pokorny T, et al. The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. Curr Biol. 2017;27(3):451–457. doi:10.1016/J.CUB.2016.12.030
   PubMed Web of Science ®Google Scholar
• Kooijman NI, Willegers T, Reuser A, et al. Are psychedelics the answer to chronic pain: a review of current literature. Pain Pract. 2023;23(4):447–458. doi:10.1111/PAPR.13203
   PubMed Web of Science ®Google Scholar
• Bushnell MC, Čeko M, Low LA. Cognitive and emotional control of pain and its disruption in chronic pain. Nat Rev Neurosci. 2013;14(7):502–511. doi:10.1038/NRN3516
   PubMed Web of Science ®Google Scholar
• Viguier F, Michot B, Hamon M, Bourgoin S. Multiple roles of serotonin in pain control mechanisms--implications of 5-HT₇ and other 5-HT receptor types. Eur J Pharmacol. 2013;716(1–3):8–16. doi:10.1016/J.EJPHAR.2013.01.074
   PubMed Web of Science ®Google Scholar
• Nichols DE. Hallucinogens. Pharmacol Ther. 2004;101(2):131–181. doi:10.1016/j.pharmthera.2003.11.002
   PubMed Web of Science ®Google Scholar
• Whelan A, Johnson MI. Lysergic acid diethylamide and psilocybin for the management of patients with persistent pain: a potential role? Pain Manag. 2018;8(3):217–229. doi:10.2217/PMT-2017-0068
   PubMedGoogle Scholar
• Lowe H, Toyang N, Steele B, et al. The Therapeutic Potential of Psilocybin. Molecules. 2021;26(10). doi:10.3390/MOLECULES26102948
   Web of Science ®Google Scholar
• De Gregorio D, Posa L, Ochoa-Sanchez R, et al. The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT1A, D2 and TAAR1 receptors. Pharmacol Res. 2016;113(Pt A):81–91. doi:10.1016/J.PHRS.2016.08.022
   PubMedGoogle Scholar
• Nichols DE. Psychedelics. Pharmacol Rev. 2016;68(2):264–355. doi:10.1124/PR.115.011478
   PubMed Web of Science ®Google Scholar
• Flanagan TW, Nichols CD. Psychedelics as anti-inflammatory agents. Int Rev Psychiatry. 2018;30(4):363–375. doi:10.1080/09540261.2018.1481827
   PubMed Web of Science ®Google Scholar
• Ogawa N, Kawai H, Terashima T, et al. Gene therapy for neuropathic pain by silencing of TNF-α expression with lentiviral vectors targeting the dorsal root ganglion in mice. PLoS One. 2014;9(3). doi:10.1371/JOURNAL.PONE.0092073
   Web of Science ®Google Scholar
• Leung L, Cahill CM. TNF-alpha and neuropathic pain--a review. J Neuroinflammation. 2010;7. doi:10.1186/1742-2094-7-27
   PubMed Web of Science ®Google Scholar
• Schindler EAD. Psychedelics as preventive treatment in headache and chronic pain disorders. Neuropharmacology. 2022;215. doi:10.1016/J.NEUROPHARM.2022.109166
   Google Scholar
• National Institute for Health and Care Excellence. Evidence review for pain management programmes for chronic pain (chronic primary pain and chronic secondary pain). Evidence review for pain management programmes for chronic pain (chronic primary pain and chronic secondary pain): chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain; Evidence review C; 2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK569980/. Accessed August 5, 2023.
   Google Scholar
• The Lancet. Rethinking chronic pain. Lancet. 2021;397(10289):2023. doi:10.1016/S0140-6736(21)01194-6
   PubMed Web of Science ®Google Scholar
• Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and Explanation. Ann Intern Med. 2018;169:467–473. doi:10.7326/M18-0850
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7). doi:10.1371/JOURNAL.PMED.1000097
   Web of Science ®Google Scholar
• Sun F, Oyesanmi O, Fontanarosa J, Reston J, Guzzo T, Schoelles K Literature Search Methods; 2014. Available from: https://www.ncbi.nlm.nih.gov/books/NBK269313/. Accessed July 30, 2023.
   Google Scholar
• Troxler F, Hofmann A. Substitutionen am ringsystem der lysergsäure I. substitutionen am indol‐stickstoff. 43. Mitteilung über mutterkornalkaloide. Helv Chim Acta. 1957;40(6):1706–1720. doi:10.1002/hlca.19570400619
   Web of Science ®Google Scholar
• Sicuteri F. Prophylactic treatment of migraine by means of lysergic acid derivatives - PubMed triangle; 1963. Available from: https://pubmed.ncbi.nlm.nih.gov/14087164/. Accessed August 2, 2023.
   Google Scholar
• Schlag AK, Aday J, Salam I, Neill JC, Nutt DJ. Adverse effects of psychedelics: from anecdotes and misinformation to systematic science. J Psychopharmacol. 2022;36(3):258. doi:10.1177/02698811211069100
   PubMed Web of Science ®Google Scholar
• Tullis P. How ecstasy and psilocybin are shaking up psychiatry. Nature. 2021;589(7843):506–509. doi:10.1038/D41586-021-00187-9
   PubMedGoogle Scholar
• Yehuda R, Lehrner A. Psychedelic therapy—a new paradigm of care for mental health. JAMA. 2023;330(9):813–814. doi:10.1001/JAMA.2023.12900
   PubMed Web of Science ®Google Scholar
• de Gregorio D, Aguilar-Valles A, Preller KH, et al. Hallucinogens in mental health: preclinical and clinical studies on LSD, psilocybin, MDMA, and ketamine. J Neurosci. 2021;41(5):891. doi:10.1523/JNEUROSCI.1659-20.2020
   PubMed Web of Science ®Google Scholar
• De La Rosa JS, Brady BR, Ibrahim MM, et al. Co-occurrence of chronic pain and anxiety/depression symptoms in U.S. adults: prevalence, functional impacts, and opportunities. Pain. 2023. doi:10.1097/J.PAIN.0000000000003056
   PubMedGoogle Scholar
• Vadivelu N, Kai AM, Kodumudi G, Babayan K, Fontes M, Burg MM. Pain and Psychology—A Reciprocal Relationship. Ochsner J. 2017;17(2):173. doi:10.1043/TOJ-17-0004
   PubMed Web of Science ®Google Scholar